heart valve technology News
-
Colibri Heart Valve Strengthens Patent Portfolio with Receipt of 12th Transcatheter Heart Valve (THV) Patent
Colibri Heart Valve LLC, a privately held emerging medical device company, has received an Issue Notification from the U.S. Patent and Trademark Office regarding the forthcoming granting of U.S. Patent No. 9,125,739 (the “’739 Patent”) titled, “Percutaneous Replacement Heart Valve and a Delivery and Implantation System.” This will be Colibri’s 12th ...
-
Colibri Heart Valve Receives European Patent for a Method of Making a Pre-packaged, Sterilized Dry Heart Valve, Pre-mounted on a Delivery Catheter
Colibri Heart Valve LLC, a privately held emerging medical device company, has received notification from the European Patent Office that patent application No. 11751242.6 titled, “Percutaneously Deliverable Heart Valve and Methods Associated Therewith” has been granted and is expected to publish as European Patent No. 2542184 (the “European Patent”) on May 25, 2016. This ...
-
Colibri Heart Valve Receives ISO 13485 and EN ISO 13485 Certification
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announced today that it has received certification from DEKRA Certification B.V. that the company complies with the European requirements of ISO 13485 and EN ISO 13485 for a comprehensive quality management system for the design and manufacture of the company’s pre-packaged, ...
-
Novostia Obtains EUR 2.5 Million Grant from the European Union To Support Its Heart Valve Technology
Neuchâtel, Switzerland, January 14, 2020 – Novostia announces that it has been awarded EUR 2.5 million grant from the European Union under the highly competitive Horizon 2020 EIC Accelerator. The EIC Accelerator is part of the European Innovation Council (EIC) pilot that supports top class companies with funding opportunities and acceleration services to help them develop and bring ...
By Novostia SA
-
You live and learn
To better understand the needs of new medical markets, it has great importance for us to directly talk to end users. One of these end users is Prof. Reuthebuch who is Deputy Senior Physician of Cardiac Surgery in the university hospital in Basel. Together with him, we have evaluated in which part of a transcatheter heart valve implantation our navigation technology could provide benefits. This ...
-
Colibri Heart Valve Continues Enrollment in Clinical Feasibility Study of Second-Generation TAVI System
Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that the Colibri transcatheter aortic valve implantation (TAVI) System has been used on an additional four patients in the ongoing international, single-arm, open-label early feasibility study (EFS). Initial post-implantation results from these patients, who received a 24mm valve, show favorable low aortic ...
-
Colibri Heart Valve Advances Second-Generation TAVI System into Clinical Feasibility Study
Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that the first two patients have been successfully enrolled in a clinical early feasibility study (EFS) of the company’s disruptive second-generation ready-for-use balloon-expandable transcatheter aortic valve implantation (TAVI) system. As with Colibri’s earlier generation system, this TAVI ...
-
Novostia technology for heart valve prosthesis raises CHF 6.5 million to start first clinical trials
Neuchâtel, Switzerland, February 22, 2019 – Novostia announces that it raised CHF 6.5 million from private investors to advance its disruptive aortic and mitral heart valve to clinical trials. Heart valve diseases affect more than 100 million people worldwide. Every year hundreds of thousands of patients undergo a heart valve replacement. Available technologies entail serious ...
By Novostia SA
-
Colibri Heart Valve Announces Issuance of a Patent for a Pre-mounted, Pre-packaged, Sterilized Dry Heart Valve on a Delivery System
Colibri Heart Valve, LLC, a privately held medical device company, has been granted yet another patent directed to prosthetic heart valves. More particularly, today the U.S. Patent & Trademark Office granted Colibri U.S. Patent No. 8,361,144 entitled, “Percutaneously Deliverable Heart Valve Device And Methods Associated Therewith.” The patent is directed to a method of making a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you